Table 1.

Patient characteristics with rheumatoid arthritis associated with psoriasis.

The age of RA onset	Comorbidity	Immunoserology	Actual clinical status	DMARD therapy	Response to DMARD	Corticosteroids (mg PED)	Biological therapy	Response to biology therapy	Psoriatic arthritis
63 yrs	Hypertension	ANA, ACPA	Remission	Sulfasalazine-leukopenia, oral methotrexate-gastrointestinal side effect, cyclosporine-with golimumab	Nonresponder	—	Golimumab	Remission	Axial
46 yrs	—	RF, ACPA, ANA	Remission	Oral methotrexate-ineffective, sulfasalazine-gastrointestinal side effect	Nonresponder	—	Etanercept	Remission	Peripheral
59 yrs	Systemic sclerosis	RF, ACPA, ANA	Remission	Chloroquine-gastrointestinal side effect sulfasalazine	Nonresponder	—	Adalimumab-ineffective, rituximab	Remission	Peripheral
32 yrs	Hypertension	RF, ACPA, ANA	Active polyarthritis	Oral methotrexate-bone marrow toxicity azathioprine-ineffective cyclosporine-ineffective combination of chloroquine, sulfasalazine, oral methotrexate-GI side effect subcutaneous methotrexate	Ineffective	>7.5 continuously	Adalimumab-ineffective etanercept-ineffective golimumab-ineffective	Nonresponder	Peripheral and axial
40 yrs	Sjögren's syndrome, neurofibromatosis	RF, ACPA, ANA, aCL IgM	Severe glandular symptoms, active polyarthritis	Leflunomide-ineffective, oral methotrexate-hepatotoxicity	Nonresponder	—	Etanercept	Just started	Peripheral

RA: rheumatoid arthritis, ANA: anti-nuclear antibody, ACPA: anti-citrullinated peptide antibody, aCL IgM: anti-cardiolipin antibody immunoglobulin M, DMARD: disease-modifying antirheumatic drugs, and PED: prednisolone equivalent dose.